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Isoprenoid Biosynthesis Inhibition Disrupts Rab5 Localization and
Food Vacuolar Integrity in Plasmodium falciparum
Ruth Howe,a Megan Kelly,a John Jimah,b Dana Hodge,a Audrey R. Odoma,b
Departments of Pediatricsa and Molecular Microbiology,b Washington University School of Medicine, St. Louis, Missouri, USA
The antimalarial agent fosmidomycin is a validated inhibitor of the nonmevalonate isoprenoid biosynthesis (methylerythritol
4-phosphate [MEP]) pathway in the malaria parasite, Plasmodium falciparum. Since multiple classes of prenyltransferase inhib-
itors kill P. falciparum, we hypothesized that protein prenylation was one of the essential functions of this pathway. We found
that MEP pathway inhibition with fosmidomycin reduces protein prenylation, confirming that de novo isoprenoid biosynthesis
produces the isoprenyl substrates for protein prenylation. One important group of prenylated proteins is small GTPases, such as
Rab family members, which mediate cellular vesicular trafficking. We have found that Rab5 proteins dramatically mislocalize
upon fosmidomycin treatment, consistent with a loss of protein prenylation. Fosmidomycin treatment caused marked defects in
food vacuolar morphology and integrity, consistent with a defect in Rab-mediated vesicular trafficking. These results provide
insights to the biological functions of isoprenoids in malaria parasites andmay assist the rational selection of secondary agents
that will be useful in combination therapy with new isoprenoid biosynthesis inhibitors.
Severe malaria due to infection with the protozoan parasitePlasmodium falciparum has a significant impact on global
health (1). Infections with P. falciparum contribute nearly 1 mil-
lion deaths per year (2). Malaria control efforts are hampered by
resistance to existing antimalarial agents, particularly chloroquine
(3, 4). Clinical resistance to themore recently introduced artemis-
inin-based therapies has already been reported, highlighting the
ongoing need to identify and exploit new targets for antimalarial
drug development (5, 6).
Isoprenoid biosynthesis is a promising antimalarial drug tar-
get. Unlike mammalian cells, plasmodia do not use the classically
described metabolic route via mevalonate. Instead, the malaria
parasite produces isoprenoids through a mevalonate-indepen-
dent pathway, which proceeds through a different keymetabolite,
methylerythritol 4-phosphate (MEP) (7, 8).P. falciparum requires
isoprenoid biosynthesis through the MEP pathway during intra-
erythrocytic development, the stage of parasite growth responsi-
ble for the clinical symptoms of malaria. The genetic locus for the
first dedicated enzyme of this pathway (deoxyxylulose-5-phos-
phate reductoisomerase [DXR]) is resistant to genetic disruption
in P. falciparum and the related apicomplexan Toxoplasma gondii,
and chemical inhibition of the MEP pathway by the small mole-
cule fosmidomycin is lethal to malaria parasites (8–10). Fosmido-
mycin treatment of cells inhibits two enzymes of theMEPpathway
(DXR and methylerythritol phosphate cytidyltransferase [IspD]),
and growth inhibition by fosmidomycin is rescued by supplemen-
tation with downstream isoprenoids, such as isopentenyl pyro-
phosphate and geranylgeraniol (11, 12). Altogether, these studies
validate the MEP pathway as an antimalarial drug target and es-
tablish the specificity of fosmidomycin as a chemical probe to
address isoprenoid biology in P. falciparum.
Isoprenoids comprise a diverse class of cellularmolecules, with
over 20,000 natural isoprenoids described (13). The pathogenic
stage of P. falciparum occupies a highly unusual ecological niche
within human red blood cells and has several peculiar metabolic
features that make it unclear which isoprenoids are essential in P.
falciparum. For example, although isoprenoids contribute to
membrane stability (as cholesterol), the malaria parasite acquires
cholesterol from host cells and does not synthesize sterols de novo
(14). In contrast, both ubiquinone biosynthesis and protein pre-
nylation appear to be required for P. falciparum development.
Ubiquinone, derived from isoprenoids, is an electron carrier and a
necessary cofactor for the P. falciparum pyrimidine biosynthesis
enzyme dihydroorotate dehydrogenase (DHODH), which is vital
for malaria parasite growth (15). Protein prenylation is the post-
translational modification of proteins, such as small GTPases,
with either farnesyl (15-carbon) or geranylgeranyl (20-carbon)
isoprenyl groups. Isoprenyl moieties are covalently attached to
C-terminal cysteines by one of three well-characterized prenyl-
transferases, which are expressed during the intraerythrocytic cy-
cle (16, 17).Multiple classes of prenyltransferase inhibitors kill the
malaria parasite, strongly suggesting that protein prenylation is an
essential function of isoprenoid biosynthesis in malaria (18–21).
In our approach, we used the isoprenoid biosynthesis inhibitor
fosmidomycin to address the role of protein prenylation as an
essential function of isoprenoids in P. falciparum. In these studies,
we confirm that ubiquinone is not the sole required isoprenoid in
malaria parasites. We demonstrate that de novo isoprenoid bio-
synthesis via the MEP pathway generates the isoprenyl precursors
for protein prenylation and that nonprenylated proteins are mis-
localized upon fosmidomycin treatment. Finally, we demonstrate
that inhibition of isoprenoid biosynthesis causes a late develop-
mental arrest and vesicular trafficking defect in malaria parasites,
consistent with a loss of protein prenylation.
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Materials. All buffer components, salts, and enzyme substrates were pur-
chased from Sigma, unless otherwise indicated.
Plasmodium falciparum culture and strains. P. falciparum strains
were cultured in vitro in human erythrocytes, as described previously (12),
with the following modifications: a 5%O2–5%CO2–90%N2 atmosphere
in RPMI 1640 medium supplemented with 27 mM sodium bicarbonate,
11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypo-
xanthine, 0.01 mM thymidine, 0.25 mg/ml gentamicin (Goldbio), and
0.5%Albumax (Invitrogen). The following strainswere obtained from the
Malaria Research and Reference Reagent Resource Center (MR4): wild-
type strain 3D7 (MRA-102), D10 ACP-(leader)-GFP (MRA-568 [22]),
and D10 ACP-(signal)-GFP (MRA-570 [22]). The following strains were
kindly provided by Akhil Vaidya (Drexel University, Philadelphia, PA)
(23): parental clone D10 and transgenic D10pHHyDHOD-GFP (which
heterologously expresses yeast DHODH [yDHODH]). The following
strain was kindly provided by Daniel Goldberg (Washington University,
St. Louis, MO): 3D7pPlasmepsin-II-GFP (24).
Flow cytometric analysis. Cultures were treated twice with a 5% (wt/
vol) D-sorbitol solution during ring-stage growth to produce a 90%
synchronized culture. Each culture was resynchronized 24 h later bymag-
netic separation (MS) with MS columns and a MiniMACS separator
(Miltenyi Biotech) to remove early-stage parasites, as previously de-
scribed (25, 26). Giemsa-stained smears were used to monitor growth.
Cell cycle analysis was performed using95% synchronized Plasmodium
falciparum 3D7 cultures. Four independent strains were split to 1% par-
asitemia (percentage of infected erythrocytes), and each was divided into
four separate treatment groups (no drug, 5 M fosmidomycin [Invitro-
gen], 5 M fosmidomycin plus 5 M geranylgeraniol, or 5 M gera-
nylgeraniol). At each time point, 100 l of each culture was fixed with an
equivalent volume of fixative solution (8% paraformaldehyde–0.015%
glutaraldehyde in phosphate-buffered saline [PBS]). DNA content was
determined by staining with the fluorophore acridine orange (1.5 g/ml;
Invitrogen), followed by resolution on a BD-FACS flow cytometer, as
previously described (27). Data analysis was performed by using FlowJo
(TreeStar Inc., Ashland, OR) and Prism 5 (GraphPad Software, La Jolla,
CA) software.
Immunoblot analysis. P. falciparum 3D7 parasites were grown to ap-
proximately 10% parasitemia, synchronized by treatment with sorbitol as
described above. Newly invaded ring-stage parasites were treated with or
without 5 M fosmidomycin for 24 h. Host erythrocytes were lysed with
0.1% saponin, and parasites were harvested by centrifugation, washed
with PBS, and then stored at80°C until use. Parasite pellets were lysed
by sonication in lysis buffer (10% glycerol, 0.1% Triton X-100, 20 mM
HEPES [pH 7.5], 150 mM sodium chloride, and protease inhibitors
[Complete EDTA-free tablets; Roche]). Immunoblotting was performed
as previously described, using rabbit antifarnesyl polyclonal antibody at a
1:500 dilution (Abcam, Cambridge, MA), rabbit anti-Plasmodium falcip-
arum EIF1 antibody (kindly provided by Daniel Goldberg, Washington
University [28]) at a 1:3,000 dilution, and horseradish peroxidase (HRP)-
conjugated goat anti-rabbit immunoglobulin polyclonal antibody at a
1:10,000 dilution (Invitrogen).
Microscopic analysis. P. falciparum parasites were synchronized by
treatment with sorbitol as described above. Newly invaded ring-stage par-
asites were treated with or without 5 M fosmidomycin, 5 M fosmido-
mycin plus 5 M geranylgeraniol, or 5 M wortmannin. Live cells were
visualized as previously described (24), and images of live cells and Gi-
emsa-stained slides were obtained with an Olympus BH8 microscope.
Live cells were stained with Lysotracker Red DND-99 (LR) (Molecular
Probes) at 75 nM for 15 min, washed in an equal volume of fresh culture
medium, and visualized immediately for no longer than 15 min. For im-
munofluorescence microscopy, cells were fixed in 4% paraformaldehyde
with orwithout 0.0075%glutaraldehyde and stored at 4°C. Fixed parasites
were permeabilized, blocked, and incubated with antibodies, as previ-
ously described (29). Rabbit polyclonal antibodies against recombinant P.
falciparumRab5a (Pf-Rab5a) and Pf-Rab5c were kindly provided by Gor-
don Langsley (Institut Cochin, France) (30) and were used at 1:500 and
1:1,000 dilutions, respectively. The secondary antibody used was Alexa
Fluor 488 goat anti-rabbit IgG(HL) (catalog number A11008; Invitro-
gen) at a 1:500 dilution, and Hoechst 33258 was used as a nuclear coun-
terstain. Images were obtained with an Olympus Fluoview FV1000 con-
focalmicroscope. All images were analyzed by using ImageJ software (31).
Minimal adjustments in brightness and contrast were employed and were
applied equally to all samples.
For ultrastructural analysis, Plasmodium-infected red blood cells were
fixed in 1% glutaraldehyde (Polysciences Inc., Warrington, PA)–1% os-
mium tetroxide (Polysciences Inc.) in 50 mM phosphate buffer (pH 7.2)
for 1 h at 4°C. This low-osmolarity fixation was used to remove dense,
soluble cytoplasmic components, allowing unobscured membrane anal-
ysis. Cells were washed in phosphate buffer and rinsed extensively in dis-
tilled water (dH2O) prior to en bloc staining with 1% aqueous uranyl
acetate (Ted Pella Inc., Redding, CA) for 1 h. Following several rinses in
dH2O, samples were dehydrated in a graded series of ethanol and embed-
ded in Eponate 12 resin (Ted Pella Inc.). Sections of 90 nm were cut,
stained with uranyl acetate and lead citrate, and viewed on a Jeol 1200 EX
transmission electron microscope (Jeol USA, Peabody, MA) at an accel-
erating voltage of 80 kV.
RESULTS
Electron transport bypass does not confer resistance to inhibi-
tion of isoprenoid biosynthesis.De novo isoprenoid biosynthesis
through the MEP pathway is an essential metabolic pathway in
malaria parasites. Because this pathway produces a large number
of compounds, we are interested in which of these is required for
development of the malaria parasite, P. falciparum. The iso-
prenoid ubiquinone is an electron acceptor for mitochondrial
electron transport and is a necessary cofactor for the essential
pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase
(DHODH). The cytochrome bc1 complex of the electron trans-
port chain is the target of the antimalarial agent atovaquone (32).
Malaria parasites engineered to heterologously express a yeast di-
hydroorotate dehydrogenase (yDHODH) homolog, which does
not require a ubiquinone cofactor, can survive withoutmitochon-
drial respiration and are resistant to atovaquone (23).Ubiquinone
biosynthesis is therefore expected to be one of the essential func-
tions of isoprenoids in malaria parasites.
In order to determine whether there are other essential func-
tions of isoprenoids, we evaluated whether yDHODH expression
also conferred resistance to inhibition of isoprenoid biosynthesis,
using the validated MEP pathway inhibitor fosmidomycin. We
obtained a strain of P. falciparum that heterologously expresses
yDHODH. We independently confirmed that this strain is resis-
tant to atovaquone, as was previously shown (data not shown)
(23). We compared the fosmidomycin concentration that inhib-
ited 50% of growth (IC50) at 3 days between the yDHODH-ex-
pressing strain and its parental control line. The yDHODH-ex-
pressing strain was as sensitive to fosmidomycin as the control
parasite line (mean IC50 of 1.2M[95% confidence interval {CI},
0.66 to 2.3], compared to the mean IC50 of the wild-type strain,
0.88 M [95% CI, 0.67 to 1.14]) (Fig. 1). Since expression of
yDHODH does not confer fosmidomycin resistance, ubiquinone
production is not likely to be the only essential function of iso-
prenoid biosynthesis in malaria parasites.
Inhibitionof isoprenoidbiosynthesis reducesproteinpreny-
lation. We evaluated whether inhibition of de novo isoprenoid
biosynthesis by fosmidomycin, which should reduce the concen-
tration of isoprenyl precursors, would reduce protein prenylation.
Howe et al.
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We analyzed whole protein lysates from parasites grown with and
without fosmidomycin (5M, approximately five times the IC50)
by immunoblotting with a rabbit polyclonal antifarnesyl antibody
that recognizes both farnesyl and geranylgeranyl groups. Previous
experiments inwhichP. falciparumwasmetabolically labeledwith
[3H]farnesol demonstrated a characteristic protein banding pat-
tern of two dominant prenylated bands, one at 45 kDa and the
other at 20 to 25 kDa (16, 33). We found that immunoblotting of
parasite lysates with antifarnesyl antibody recapitulated this band-
ing pattern, consistent with the identification of these bands as
prenylated proteins (Fig. 2). We used a densitometric evaluation
of band intensities to compare prenylation with and without fos-
midomycin treatment. The intensity of antifarnesyl staining of the
25-kDa lower band was reduced by 97% following fosmidomy-
cin treatment (normalized to the density of control Pf-EF1 im-
munoblotting of the sameblot). The intensity of the upper 45-kDa
band, the identity of which is unknown, was reduced by 30%
following fosmidomycin treatment. These results indicate that the
isoprenyl moieties used for protein prenylation are derived from
de novo isoprenoid biosynthesis in P. falciparum and that inhibi-
tion of isoprenoid biosynthesis reduces protein prenylation.
RabGTPases aremislocalizedwhen isoprenoid biosynthesis
is inhibited. Fosmidomycin inhibited protein prenylation and
particularly reduced prenylation of proteins of around 25 kDa.
The malaria parasite expresses at least 11 small GTPases with pre-
dicted molecular masses of between 23 and 27 kDa, each of which
is predicted to be geranylgeranylated (34, 35). These proteins
likely comprise the dominant band that labels with [3H]farnesol
and are recognized by antifarnesyl antibodies at 25 kDa (16). Since
protein prenylation is typically required for the localization and
function of small GTPases, such as Rab5 family members, we ex-
amined the localization of two candidate geranylgeranyltrans-
ferase substrates, Pf-Rab5a and Pf-Rab5c. Rab5 proteins are pro-
totypical markers of early endosomal vesicles in most eukaryotic
cells, and Pf-Rab5a was previously localized by immunoelectron
microscopy to small hemoglobin-containing vesicles in P. falcip-
arum (36). Pf-Rab5a and Pf-Rab5c were dispersed in punctae
throughout malaria parasite cells (Fig. 3). Upon fosmidomycin
treatment, a dramatic mislocalization of Rab5a occurred in the
majority of treated cells, such that Rab5a was no longer present
within the parasite cell but instead was found at the membrane of
the host erythrocyte. Similarly, fosmidomycin treatment mislo-
calized Rab5c, which became diffusely localized throughout both
the parasite cell and the host erythrocyte cytoplasm. Previous
studies demonstrated that the antimalarial effects of fosmidomy-
cin are rescued bymedium supplementationwith the downstream
isoprenol geranylgeraniol, which we confirmed (see Fig. S1 in the
supplemental material) (11, 12). Localizations of both Rab5a and
Rab5c were restored by medium supplementation with gera-
nylgeraniol, demonstrating that this effect of fosmidomycin was
also due to inhibition of isoprenoid biosynthesis. To quantify
these observations, a series of independent representative images
(50 cells under each condition) were scored on a scale of 1 to 3
(where 1 represents a typical intracellular localization and 3 rep-
resents primarily erythrocyte membrane staining) by a trained
observer who was blinded to the treatment conditions (Fig. 3C).
The cellular distributions of Pf-Rab5a and Pf-Rab5c were signifi-
cantly altered upon fosmidomycin treatment (P 0.001 for each
[t test]).
Inhibition of isoprenoid biosynthesis causes developmental
arrest during schizogony. Our data indicate that the MEP path-
way generates the isoprenyl groups for protein prenylation in P.
falciparum and that candidate prenylated proteins are mislocal-
ized upon fosmidomycin treatment. We next evaluated the bio-
logical effects of isoprenoid depletion on P. falciparum to assess
whether the phenotype of fosmidomycin-treated parasites was
consistent with a loss of prenylated protein function. We exam-
ined gross effects on parasite development using Giemsa staining
and light microscopy of parasites with or without fosmidomycin
treatment. Within the erythrocyte host cell, untreated P. falcipa-
rum parasites mature from newly invaded parasites with a typical
ring morphology into multinucleated schizonts. This is followed
by egress as merozoites and reinvasion, in a cycle that typically
takes approximately 48 h. We found that fosmidomycin-treated
parasites have normal gross development over the first 24 h but
arrest in the first cell cycle as schizonts, after the onset of nuclear
division but prior to segmentation of daughter merozoites (Fig.
4). To quantify the stage of this arrest, we generated highly syn-
chronized parasite cultures and monitored DNA content
throughout the development of each culture using acridine or-
ange staining and flow cytometry. At the initial time point (time
zero), each culture was highly enriched for ring-stage parasites
(95% of total cells), which had not yet begun DNA replication
FIG 2 Fosmidomycin treatment inhibits protein prenylation. (A) Antifarnesyl
immunoblot of extracts with or without treatment with 5 M fosmidomycin
(FSM) for 24 h. (B) Blot from panel A reprobed with antibodies to Pf-EIF1 to
indicate equivalent protein loading. Results are representative of at least three
independent biological replicates.
FIG 1 Bypass of electron transport does not confer fosmidomycin resistance.
Shown are data for growth inhibition by the isoprenoid biosynthesis inhibitor
fosmidomycin (FSM) in P. falciparum parasites (control) compared to para-
sites that heterologously express yeast dihydroorotate dehydrogenase, which
does not require ubiquinone (control  yDHODH). Results are the means
and standard deviations from three independent biological replicates.
Isoprenoids in Malaria
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(pre-S phase). Control and geranylgeraniol-treated parasites
completed multiple rounds of DNA replication and produced
daughter parasites (returning to pre-S phase). In contrast, thema-
jority (80%) of fosmidomycin-treated parasites entered S phase
but failed to develop further (Fig. 5). These effects of fosmidomy-
cin were reversed by medium supplemented with a downstream
isoprenol, geranylgeraniol (Fig. 5), confirming that they are spe-
cific to isoprenoid blockade. Fosmidomycin-treated parasites ar-
rest with an average DNA content of approximately 9.1  1.0 n
(where n refers to the haploid DNA content of ring-stage para-
sites), compared to control parasites, which contain an average
maximumDNA content of 15.6 1.3 n (see Fig. S2 in the supple-
mental material).
Inhibitionof isoprenoidbiosynthesis disrupts food vacuolar
morphology.BecauseRabGTPases are required for vesicular traf-
ficking in most eukaryotic cells, we further examined the ultra-
structural effects of isoprenoid biosynthesis inhibition on P. fal-
ciparum parasites. Highly synchronized cultures (enriched for
ring-stage parasites) were culturedwith or without fosmidomycin
and then fixed at the indicated time points. Typical cellular fea-
tures of P. falciparum include nuclei, mitochondria, apicoplast
organelles, as well as the food vacuole (FV), where hemoglobin
digestion occurs. We found that fosmidomycin-treated parasites
were ultrastructurally indistinguishable from control parasites at
early stages of development through early trophozoite stages
(through 16 h of drug treatment [data not shown]), including
normal formation and development of the digestive FV. By 24 h of
treatment, however, fosmidomycin-treated parasites began to
demonstrate morphological abnormalities of the FV (Fig. 6). A
typical malarial FV contains a single focus of hemozoin pigment
crystals (the final product of heme detoxification from hemoglo-
bin digestion) within a distinct food vacuolar membrane. In con-
trast, fosmidomycin-treated parasites demonstrated a variety of
abnormal FV morphologies. In less severely affected parasites,
these FVs appeared as multiple discontiguous vacuoles. In more
severely affected parasites, the vacuolar membrane was absent,
and hemozoin crystals were free within the cellular cytoplasm.
Inhibition of phosphatidylinositol 3-kinase function also
disrupts food vacuolar morphology. The morphological effects
of fosmidomycin-treated P. falciparum suggest a defect in hemo-
globin trafficking in these cells. The phosphatidylinositol 3-kinase
(PI3-K) inhibitor wortmannin was previously demonstrated to
inhibitP. falciparumPI3-K in vitro and inhibit hemoglobin uptake
in malaria parasites (37). Since Rab GTPases often function
through the activation of PI3-Ks, we hypothesized that the ultra-
structural abnormalities of fosmidomycin-treated parasites
would be similar to those of wortmannin-treated parasites. We
found that wortmannin caused a disruption in food vacuolar
morphology similar to that caused by fosmidomycin. In wort-
mannin-treated parasites, the FV appeared to be fragmented into
multiple discontiguous vacuoles (Fig. 6C). While a number of
abnormal traits characterized the FV of both fosmidomycin- and
wortmannin-treated cells, the most quantifiable change was the
loss of FV membrane or apparent fragmentation of a single FV
intomultiple FVs. A series of representative electronmicrographs
(25 cells under each condition) were scored for FVmorphology.
Abnormal FVswere defined by an absence of FVmembrane or the
presence of more than one focus of hemozoin. Using these crite-
ria, FV morphology was significantly altered upon fosmidomycin
and wortmannin treatments (P  0.001 for each [t test]). While
the ultrastructural effects that we observed differed slightly from
what was previously reported for wortmannin-treated P. falcipa-
FIG 3 Mislocalization of Rab5 proteins by fosmidomycin treatment. (A and B) Confocal immunofluorescence with either anti-PfRab5a (A) or anti-PfRab5c (B)
antibody in untreated parasites (control) compared to fosmidomycin-treated (FSM) and fosmidomycin- and geranylgeraniol-treated (FSM GG-ol)
parasites. FITC, fluorescein isothiocyanate. (C) Blinded scoring of 50 cells under each condition for severity of mislocalization of Rab5 (1, typical cellular
punctae within parasite; 2, partial mislocalization to erythrocyte or erythrocyte membrane; 3, severe mislocalization to erythrocyte or erythrocyte membrane).
, P 0.001 compared to untreated conditions.
FIG 4 Fosmidomycin treatment causes growth arrest of malaria parasites
during schizogony. Shown are Giemsa-stained light micrographs of synchro-
nized ring-stage parasites at the indicated time points of culture for compari-
son of untreated parasites (A) to those treatedwith 5Mfosmidomycin (B) or
5 M fosmidomycin plus 5 M the downstream isoprenol geranylgeraniol
(C). Images of representative cells are indicative of results from at least five
independent biological replicates.
Howe et al.
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rum, this may reflect the superior membrane preservation
achieved by the low-osmolality fixation technique used here (37).
Inhibition of isoprenoid biosynthesis or PI3-K function dis-
rupts food vacuolar integrity.Both fosmidomycin andwortman-
nin treatment of P. falciparum resulted in abnormal FVmorphol-
ogies, as visualized by electron microscopy. To independently
assess the integrity of the FV in fosmidomycin- and wortmannin-
treated parasites, we utilized a malaria parasite strain expressing
the hemoglobin-digesting enzyme plasmepsin II tagged with
green fluorescent protein (PMII-GFP). In malaria parasites,
PMII-GFP is localized to the FV (24). Using confocal immunoflu-
orescence, we confirmed that PMII-GFP was localized to the FV,
which is distinguished microscopically in phase images by the
presence of dark hemozoin pigment (Fig. 7, left). Following fos-
FIG 5 Fosmidomycin-treated parasites arrest during S phase. Shown are proportions of cells with unreplicated DNA (pre-S phase, morphologically early-ring-
stage parasites, 12 h after invasion) compared to those in which DNA replication has begun (S phase), as determined by acridine orange staining and flow
cytometric evaluation. Untreated parasites (A) are compared to fosmidomycin-treated parasites (B), fosmidomycin- and geranylgeraniol-treated parasites (C),
and parasites with geranylgeraniol treatment alone (D). The cell cycle duration under these conditions is approximately 48 h; untreated parasites return to pre-S
phase at 36 h.
FIG 6 Food vacuolar defect in fosmidomycin- and wortmannin-treated parasites. (A to C) Transmission electron microscopic evaluation of control parasites
(A) compared to parasites treated for 24 h with either the isoprenoid inhibitor fosmidomycin (B) or the PI3-K inhibitor wortmannin (C). On the right is a
magnified view of a hemozoin-containing FV. (D) Scoring of electron micrographs of control versus fosmidomycin (FSM)- and wortmannin-treated cells.
Abnormal FVs were defined as FVs that either lacked an FV membrane or contained more than one discontiguous membrane-bound collection of hemozoin
(n 25 under each condition). , P 0.001 compared to untreated conditions (Fisher’s 2-tailed test).
Isoprenoids in Malaria
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midomycin treatment, PMII-GFP was no longer discretely local-
ized within the FV. Instead, PMII-GFP was dispersed throughout
the parasite cytoplasm, consistent with the physical disruption of
the FV that was visualized by electron microscopy (Fig. 7). PMII-
GFP localization was restored by medium supplementation with
the isoprenoid geranylgeraniol, confirming that this effect of fos-
midomycin is caused by an inhibition of isoprenoid biosynthesis.
PMII-GFP was diffusely present throughout the cytoplasm of
wortmannin-treated parasites, confirming that FVs are also dis-
rupted upon PI3-K inhibition. Similar effects of fosmidomycin
and wortmannin on FV integrity were confirmed in live parasite
cells treated with Lysotracker Red (LR), a fluorophore that indi-
cates acidic organelles. LR accumulated within the FV of control
parasites but was dispersed throughout the cytoplasm of fosmido-
mycin- andwortmannin-treated parasites (Fig. 7, right). FV local-
ization was restored in fosmidomycin-treated parasites that were
rescued with medium supplementation with geranylgeraniol.
To examine the possibility that the mislocalization of PMII-
GFP was due to general defects in protein traffic or membrane
permeability, we evaluated the ability of drug-treated cells to ap-
propriately localize two additional GFP fusion proteins with well-
characterized localizations: the apicoplast localization sequence
from acyl carrier protein (ACP), ACPL-GFP (which traffics to the
apicoplast), and the signal sequence fromACP, ACPs-GFP (which
is exported to the parasitophorous vacuole space) (22). Both
ACPs- and ACPL-GFP were appropriately localized in both fos-
midomycin- and wortmannin-treated cells (Fig. 8). ACPL-GFP
fluorescence in parasites with and without drug treatments dem-
onstrated a typical apicoplast appearance, with a long, thin, single
structure early in intraerythrocytic development (38). With and
without drug treatment, ACPs-GFP fluorescence was present
within the parasitophorous vacuole andwas frequently seen in the
tubovesicular network. These results indicate that general protein
trafficking mechanisms are still in place in both fosmidomycin-
and wortmannin-treated cells and support that the FV phenotype
and PMII-GFP localization observed in these cells are not an in-
direct effect of acute cellular injury.
DISCUSSION
Isoprenoid biosynthesis via the nonmevalonate (MEP) pathway is
required for intraerythrocytic development of P. falciparum ma-
laria parasites. Fosmidomycin-treated parasites arrest in the first
cell cycle following drug treatment, in contrast to the “delayed
death” that occurs in the second cell cycle of parasites treated with
other apicoplast-targeting antimalarial agents (such as clindamy-
cin and doxycycline) (34). This is not unexpected, given that iso-
prenoids are expected to have multiple cellular functions outside
apicoplast maintenance. We find that fosmidomycin-treated par-
asites successfully generate digestive food vacuoles (FVs), initiate
hemoglobin digestion, and begin DNA replication prior to devel-
opmental arrest. De novo isoprenoid biosynthesis therefore does
not appear to be required for these complex and energy-intensive
cellular tasks, and this finding indicates a narrower role for iso-
prenoids in malaria cellular functions than had been suspected.
Our results suggest that the biological effects of isoprenoid
inhibition by fosmidomycin in P. falciparum are in part due to an
FIG 7 Loss of food vacuolar integrity upon fosmidomycin and wortmannin
treatment. Shown is the confocal fluorescence microscopic localization of a
plasmepsin II-GFP (P2-GFP) construct (left) or live fluorescence imaging of
Lysotracker Red-stained malaria parasites (right). Control parasites (A) are
compared to parasites treated for 24 hwith either fosmidomycin (B), fosmido-
mycin plus geranylgeraniol (C), or wortmannin (D). Images are representative
of at least three independent biological experiments. Visualization of PMII-
GFP in FSM- and wortmannin-treated parasites required higher detector gain
levels, resulting in increased observed erythrocyte autofluorescence.
FIG 8 Apicoplast and parasitophorous vacuolar targeting in fosmidomycin- and wortmannin-treated parasites. Shown is live-cell fluorescence of malaria
parasites that express either the leader sequence (ACPL-GFP) (A) or signal sequence (ACPs-GFP) (B) from P. falciparum acyl carrier protein, fused toGFP, which
traffic to the apicoplast or parasitophorous vacuole, respectively (27). Untreated parasites (control) are compared to fosmidomycin (FSM)- and wortmannin
(wort)-treated parasites. Images are representative of at least three independent biological experiments.
Howe et al.





ber 12, 2013 by W







inhibition of protein prenylation. While the mitochondrial elec-
tron carrier ubiquinone is also likely essential, we find thatmalaria
parasites that have been engineered to bypass the need for electron
transport remain highly sensitive to fosmidomycin. Our results
implicate at least one further essential function of isoprenoid bio-
synthesis in malaria parasites and are consistent with findings re-
ported previously by Yeh andDeRisi (unpublished data described
in reference11). We present the first evidence that the isoprenyl
metabolites used in protein prenylation are derived from de novo
isoprenoid biosynthesis, since protein prenylation is reduced by
isoprenoid biosynthesis inhibition. Protein prenylation is neces-
sary for proper protein localization and function of prenylated
proteins, and indeed, we find that inhibition of isoprenoid biosyn-
thesis causes a dramatic mislocalization of two candidate prenyl-
transferase substrates (Rab5a and Rab5c). Finally, inhibition of
isoprenoid biosynthesis causes food vacuolar morphological de-
fects that are consistent with a disruption of protein prenylation.
Inhibition of protein prenylation directly with prenyltransferase
inhibitors causes a more rapid cell cycle arrest than we observed
(16); however, this is consistentwith our previously reported find-
ings that the levels of isoprenoid precursors do not change for 6 h
following fosmidomycin treatment (12).
The intraerythrocytic stage of P. falciparum depends on diges-
tion of host cell hemoglobin as its source for most amino acids
(27). Hemoglobin is transported from the host cell to a specialized
acidic digestive structure, the FV, where proteolysis and heme
detoxification occur. Hemoglobin trafficking to the FV is a com-
plicated, actin-dependent process, the molecular details of which
have not been fully elucidated (36, 39, 40). The Rab family of small
GTPases is likely to be important for this process. There are at least
11 Rab family homologs in the P. falciparum genome (41). Of
these, Rab5 homologs in particular are important for early endo-
cytosis in other eukaryotes, including other protozoans, such as
the related apicomplexanToxoplasma gondii as well as Leishmania
donovani and Entamoeba histolytica (42–44). In P. falciparum,
Rab5a, a prototypical early endosomal marker, has been localized
to small hemoglobin-containing vesicles by immunoelectron mi-
croscopy, suggesting that these are endocytic vesicles en route to
the FV (36).
Activated GTP-bound Rab5s typically function through acti-
vation of phosphatidylinositol-3 kinases (PI3-Ks) to increase local
levels of phosphatidylinositol 3-phosphate [PI(3)P]. Although ca-
sein kinase physically associates with Rab5b, the downstream ef-
fectors of Rab5s in malaria are not known (30). A single essential,
wortmannin-sensitive PI3-K has been described for P. falciparum,
which can synthesize PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 (35, 37).
PI(3)P is the dominant phosphorylated phosphatidylinositol in
malaria-infected erythrocytes and appears to have a large number
of functional roles inmalaria parasites (35). Using specific PI(3)P-
binding proteins, PI(3)P has been localized to the food vacuole,
the apicoplast, and the endoplasmic reticulum inmalaria parasites
(35, 45, 46). Surprisingly, PI(3)P binding by export signals ap-
pears to be required formalaria protein export to the host cell, and
PI3-K itself is exported to the host erythrocyte (37, 45).
The growth arrest and morphological changes of fosmidomy-
cin-treated malaria parasites may reflect multiple cellular insults.
Decreased protein prenylation upon fosmidomycin treatment is
likely to result in mislocalization of multiple prenyltransferase
substrates, including all Rab family members. For example, a loss
of Rab5 prenylation and defective trafficking to the FV could ex-
plain the ultrastructural defects observed for fosmidomycin-
treated parasites (graphically represented in Fig. 9). Expression of
a constitutively active Rab5a (Q102L) allele produces a bloated,
enlarged FV, the opposite effect of what we observed upon fos-
midomycin treatment and Rab5 mislocalization (36). In addition
to the effects on food vacuolar morphology that we observed,
fosmidomycin was also previously reported to interrupt apico-
plast development in P. falciparum (9). The lipid PI(3)P has been
localized to both the apicoplast and food vacuole, and PI3-K in-
hibition with wortmannin disrupts apicoplast development (35,
47) and alters food vacuolar morphology (this study). While
PI(3)P signaling and isoprenoid biology are both complex, these
phenotypic similarities suggest that the two pathways could con-
verge and are consistent with the hypothesis that PI3-K may be a
Rab5 effector in P. falciparum.
Upon fosmidomycin treatment, both Rab5a and Rab5c are
found within the host erythrocyte. This mislocalization does not
appear to be due to general membrane permeability, since other
protein constructs are retained within the parasite plasma mem-
brane or parasitophorous vacuole (PMII-GFP [Fig. 7] and ACPL-
GFP and ACPs-GFP [Fig. 8]). Since neither Rab5a nor Rab5c is
predicted to contain a host-targeting (HT) or Plasmodium export
element (PEXEL) motif, the localization of these proteins to the
host cell suggests an alternate mechanism of export that is un-
masked when the proteins are not tethered by prenylation. Fur-
ther experimentation is required to determine whether there is a
population of Rabs in P. falciparum that have biological functions
within the host erythrocyte under normal growth conditions.
As novel inhibitors are developed to target nonmevalonate iso-
prenoid biosynthesis, an understanding of the biological conse-
quences of isoprenoid biosynthesis inhibition in P. falciparum
may inform the rational selection of secondary agents that will be
useful in combination therapy. For example, since fosmidomycin-
treated parasites arrest prior to completion of DNA synthesis,
FIG 9 Model of fosmidomycin effects on malaria parasites. Fosmidomycin
blocks isoprenoid biosynthesis and causes a defect in growth and vesicular
trafficking to the food vacuole (FV). These effects are rescued by gera-
nylgeraniol (GG-ol), indicating that the essential isoprenoids in malaria are
metabolically derived from geranylgeranyl pyrophosphate (GG-PP). GG-PP is
the substrate for geranylgeranyltransferase (GGTase), which modifies the en-
docytosis regulator Rab5 (a small GTPase) in most eukaryotes. Blocking of
isoprenoid biosynthesis (with fosmidomycin) decreases protein prenylation,
causes Rab5 mislocalization, and alters FV morphology. IPP, isopentenyl py-
rophosphate; DMAPP, dimethylallyl pyrophosphate.
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small molecules that act on parasite egress, such as PfSUB1 pro-
tease inhibitors (48), may be less useful alongside inhibition of
isoprenoid biosynthesis. Our results suggest that parasite-specific
prenyltransferase inhibitors may be particularly useful in combi-
nation antimalarial therapy with isoprenoid biosynthesis inhibi-
tors.
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